New hope for tough pancreatic cancer? experimental combo enters human testing
NCT ID NCT03301805
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental oral liquid called BLEX 404 combined with standard chemotherapy (gemcitabine) in 40 people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study first finds a safe dose, then checks if the combo shrinks tumors or slows the disease. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BLEX 404 oral liquid combined with gemcitabine chemotherapy
What this could lead to
If successful, this could point toward a new combination treatment that helps control advanced pancreatic cancer for a time.
What could go wrong
This is an early phase 2 trial with only 40 people, so results may not apply broadly. The drug combo may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••